Sharp Therapeutics (TSXV:SHRX) Short Percentage of Float


TSXV:SHRX Sharp Therapeutics Corp TSXV:SHRX
15 GF Score
Price C$0.91
View Full Analysis

What is Sharp Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TSXV:SHRX vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Sharp Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sharp Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sharp Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Sharp Therapeutics's Short Percentage of Float falls into.


TSXV:SHRX
15GF Score
Sharp Therapeutics Corp TSXV:SHRX
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sharp Therapeutics Business Description

Address 2403 Sidney Street, Suite 264, Pittsburgh, PA, USA, 15203
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
15GF Score

Get the complete analysis for TSXV:SHRX

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.91
Price